Vistin Pharma ASA VISTN
Oslo Børs · Healthcare · Drug Manufacturers - Specialty & Generic
18.85 NOK
+1.9%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Vistin Pharma
| NOK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 288 | 435 | 429 | 452 |
| EBITDA | 8 | 78 | 102 | 120 |
| Net income | −5 | 46 | 63 | 75 |
| Balance sheet | ||||
| Equity | 273 | 323 | 310 | 329 |
| Total debt | 48 | 2 | 1 | 1 |
| Cash | 1 | 26 | 13 | 16 |
| Net debt | 47 | −24 | −11 | −16 |
| Ratios and per share | ||||
| EBITDA margin | 2.9% | 17.9% | 23.7% | 26.6% |
| Profit margin | −1.6% | 10.5% | 14.6% | 16.5% |
| Return on equity | −1.7% | 14.1% | 20.3% | 22.7% |
| Earnings/share (NOK) | −0.11 | 1.03 | 1.42 | 1.69 |
| Book value/share (NOK) | 6.17 | 7.28 | 6.98 | 7.41 |
| Shares outstanding (M) | 44 | 44 | 44 | 44 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 11.2 |
| P/B | 2.5 |
| EV / EBITDA | 6.8 |
| Net debt / EBITDA | −0.1 |
| Return on equity | 22.7% |
| Profit margin | 16.5% |
| Beta 1Y | 0.20 |
| Revenue growth 1Y | +5.4% |
| Revenue CAGR 3Y | +16.3% |
| ROE avg. 3Y | 19.0% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (NOK)
| 2026 | 1.00 |
| 2025 | 1.25 |
| 2024 | 1.75 |
Not investment advice. Figures may contain errors from the data source.